These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 19019404)

  • 41. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
    Paredes R; Puertas MC; Bannister W; Kisic M; Cozzi-Lepri A; Pou C; Bellido R; Betancor G; Bogner J; Gargalianos P; Bánhegyi D; Clotet B; Lundgren J; Menéndez-Arias L; Martinez-Picado J;
    J Infect Dis; 2011 Sep; 204(5):741-52. PubMed ID: 21844300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
    Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
    Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA(Lys3) into HIV-1.
    Khorchid A; Javanbakht H; Wise S; Halwani R; Parniak MA; Wainberg MA; Kleiman L
    J Mol Biol; 2000 May; 299(1):17-26. PubMed ID: 10860720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interplay between protease and reverse transcriptase dimerization in a model HIV-1 polyprotein.
    Chagas BCA; Zhou X; Guerrero M; Ilina TV; Ishima R
    Protein Sci; 2024 Jul; 33(7):e5080. PubMed ID: 38896002
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gag-Pol bearing a reverse transcriptase drug-resistant mutation influences viral genomic RNA incorporation into human immunodeficiency virus type 1 particles.
    Aguiar RS; Pereira HS; Costa LJ; Brindeiro RM; Tanuri A
    J Gen Virol; 2006 Sep; 87(Pt 9):2669-2677. PubMed ID: 16894207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag.
    Zhou J; Chen CH; Aiken C
    J Virol; 2006 Dec; 80(24):12095-101. PubMed ID: 17035324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutations in the thumb allow human immunodeficiency virus type 1 reverse transcriptase to be cleaved by protease in virions.
    Dunn LL; McWilliams MJ; Das K; Arnold E; Hughes SH
    J Virol; 2009 Dec; 83(23):12336-44. PubMed ID: 19759158
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells.
    Pattyn E; Lavens D; Van der Heyden J; Verhee A; Lievens S; Lemmens I; Hallenberger S; Jochmans D; Tavernier J
    J Virol Methods; 2008 Oct; 153(1):7-15. PubMed ID: 18640157
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Foamy retrovirus integrase contains a Pol dimerization domain required for protease activation.
    Lee EG; Roy J; Jackson D; Clark P; Boyer PL; Hughes SH; Linial ML
    J Virol; 2011 Feb; 85(4):1655-61. PubMed ID: 21123385
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structural and dynamical aspects of HIV-1 protease and its role in drug resistance.
    Meher BR; Patel S
    Adv Protein Chem Struct Biol; 2013; 92():299-324. PubMed ID: 23954105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biophysical Characterization of p51 and p66 Monomers of HIV-1 Reverse Transcriptase with Their Inhibitors.
    Seetaha S; Kamonsutthipaijit N; Yagi-Utsumi M; Seako Y; Yamaguchi T; Hannongbua S; Kato K; Choowongkomon K
    Protein J; 2023 Dec; 42(6):741-752. PubMed ID: 37728788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV-1 reverse transcriptase stability correlates with Gag cleavage efficiency: reverse transcriptase interaction implications for modulating protease activation.
    Hsieh SH; Yu FH; Huang KJ; Wang CT
    J Virol; 2023 Sep; 97(9):e0094823. PubMed ID: 37671867
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of reduced gag cleavage efficiency on HIV-1 Gag-Pol package.
    Lin YR; Chu SM; Yu FH; Huang KJ; Wang CT
    BMC Microbiol; 2022 Apr; 22(1):94. PubMed ID: 35395730
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amino acid substitutions at the HIV-1 transframe region significantly impair virus infectivity.
    Yu FH; Huang KJ; Wang CT
    PLoS One; 2022; 17(1):e0262477. PubMed ID: 35085286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human Transbodies to Reverse Transcriptase Connection Subdomain of HIV-1 Gag-Pol Polyprotein Reduce Infectiousness of the Virus Progeny.
    Seesuay W; Phanthong S; Densumite J; Mahasongkram K; Sookrung N; Chaicumpa W
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452018
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Large Multidomain Protein NMR: HIV-1 Reverse Transcriptase Precursor in Solution.
    Ilina TV; Xi Z; Brosenitsch T; Sluis-Cremer N; Ishima R
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333923
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.